(Reuters) - Valeant Pharmaceuticals International Inc said it is prepared to improve its offer for Allergan Inc to at least $200 per share.
The Botox maker's shares closed at $184.21 on Friday.
Valeant Chief Executive Michael Pearson said in a letter to ALLERGAN (AGN.NY)s board that Allergan's stock would not be trading at the multiples it is now if it were not for Valeant's offer.
Pearson told Reuters last week that a possible revised stock-and-cash bid would be worth more than $200 per share, assuming that Valeant's stock rises, and would include more cash.
(Reporting by Sayantani Ghosh in Bangalore; Editing by Sriraj Kalluvila)
Relacionados
- El aeropuerto de Dubai eleva un 6,2% el tráfico de pasajeros hasta septiembre, con 52,4 millones
- El aeropuerto peruano de Talara prevé 50.000 pasajeros al año tras su modernización
- La OMS dice control de ébola a pasajeros de avión puede tener un "efecto limitado"
- OMS dice control por ébola a pasajeros que lleguen por avión podría tener "efecto limitado"
- La Guardia Civil auxilia a 55 pasajeros de un autobús que se quedó sin combustible en Luciana (Ciudad Real)
